Healthcare >> CEO Interviews >> July 28, 2003
DR. PAUL J. KELLY joined Orchid BioSciences, Inc., as Chief Executive
Officer in June 2003. From 1995 to 2001, Dr. Kelly served as CEO of
Gemini Genomics, a clinical genomics company which he co-founded in 1995
to discover and commercialize novel gene-based targets. At Gemini, Dr.
Kelly positioned the company for the largest biotech IPO in the UK, and
he completed acquisitions in Sweden and Canada. In 2001, Dr. Kelly
oversaw the company's successful merger with Sequenom. Before becoming a
biotechnology executive, Dr. Kelly had a distinguished career as a
physician specializing in endocrinology in Australia, authoring more
than 90 scientific publications while serving as Senior Research
Physician at the Garvan Institute for Medical Research in Sydney. Since
leaving Gemini, Dr. Kelly helped found three companies in the health
sciences arena, and most recently served as CEO and Executive Director
of OmniViz, Inc., a leader in enabling the visualization of disparate
data sets for faster and more efficient decision-making. Dr. Kelly has
served on national governmental advisory bodies as well as on the Boards
of public and private companies. He currently is a director of Nanovis,
MedCenter Solutions and AgaMatrix. Dr. Kelly is a graduate of the
University of New South Wales where he received his Bachelor of
Medicine, Bachelor of Surgery (honors) and Doctor of Medicine degrees.
He is a Fellow of the Australasian College of Physicians. Profile
Dr. Kelly: Orchid BioSciences is the leading provider of identity
genomics services for the forensic and paternity DNA testing
